<DOC>
	<DOCNO>NCT00130364</DOCNO>
	<brief_summary>This study conduct United States America ( USA ) . Atopic dermatitis , also call eczema , characterize redness , papulation ( skin elevation ) pruritus ( skin itching ) . The active ingredient pimecrolimus inhibit T-cell activation . These cell involve inflammatory component disease . This study test safety efficacy pimecrolimus cream 1 % atopic dermatitis face patient intolerant , dependent , topical corticosteroid .</brief_summary>
	<brief_title>Efficacy Safety Pimecrolimus Cream 1 % Patients ( 2 11 Years Old ) With Mild Moderate Facial Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Mild moderate facial atopic dermatitis Patients intolerant , dependent , topical corticosteroid Concurrent skin disease ( infection ) Immunocompromised Recently receive phototherapy systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>T-cell</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>child</keyword>
	<keyword>facial</keyword>
	<keyword>Facial atopic dermatitis</keyword>
</DOC>